Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
$5.5M will support CyVek's commercialization of immunoassay
A Series D funding round has brought in $5.5 million for CyVek, which will use the proceeds for the market launch of the firm's CyPlex immunoassay platform. CyPlex can be used to examine multiple biomarkers from samples.
Or we can send an email on your behalf